source
- Adicet Bio's off-the-shelf CAR-T therapy shows lupus remission in early Phase 1 trialAdicet Bio reported that its off-the-shelf CAR-T product prula-cel induced remission in more than half of lupus patients enrolled in a small Phase 1 study. One year after a single infusion, 12 of…
- Azalea Therapeutics wins Endpoints 11 award, combines gene editing with CAR-T and raises $82 millionAzalea Therapeutics was named the winner of the Endpoints 11 2026 competition, highlighting its innovative approach in the biotech space. The company’s platform merges precise gene‑editing techniq…